Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + tocilizumab
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Dexamethasone + tocilizumab is a combination therapy that pairs a synthetic glucocorticoid (dexamethasone) with a humanized monoclonal antibody IL-6 receptor inhibitor (tocilizumab). This combination has shown significant efficacy in treating severe COVID-19 by providing complementary anti-inflammatory effects. Dexamethasone offers broad anti-inflammatory properties while tocilizumab specifically blocks IL-6 signaling, which is implicated in the cytokine storm associated with severe COVID-19. Clinical trials have demonstrated that this combination reduces mortality, shortens hospital and ICU stays, decreases oxygen requirements, and improves clinical recovery compared to dexamethasone alone.
02
Targets
Beyond the preview
Go deeper on dexamethasone + tocilizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + tocilizumab.